ALY-501

ALY-501 is a therapeutic peptide being developed by Alys Pharmaceuticals for the treatment of chronic pruritus (itch). It acts as an antagonist of the Mas-related G-protein coupled receptor member X4 (MRGPRX4), a receptor primarily expressed in sensory neurons that plays a key role in mediating itch signals, particularly in conditions like cholestatic pruritus. By inhibiting MRGPRX4, ALY-501 aims to provide relief for patients suffering from persistent, debilitating itch that is poorly managed by existing therapies. The drug is part of Alys's broader strategy to utilize diverse modalities, including peptides and siRNAs, to address unmet needs in dermatology.